Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

Response and survival, trial by trial.

Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.

7 arms have a reported figure in this set.

Avapritinib 1

Avapritinib

Avapritinib 300 mg

300 mg · ITT

3L or later GIST (n = 240)

Comparator: regorafenib 160 mg

progression-free survival hazard ratio vs regorafenib: 1.25 HR, primary analysis; P = .055

VOYAGER · NCT03465722

Bezuclastinib + Sunitinib 1

Bezuclastinib + Sunitinib

Bezuclastinib 600 mg + sunitinib 37.5 mg

600 mg + 37.5 mg · ITT

GIST after imatinib (n = 204)

Comparator: sunitinib 37.5 mg

progression-free survival hazard ratio vs sunitinib: 0.5 HR, data cutoff 09.30.2025

PFS2 hazard ratio vs sunitinib: 0.57 HR, ASCO 2026 update

Peak · NCT05208047

Imatinib 2

Imatinib

Imatinib 400 mg for 12 months

400 mg · ITT

resected primary GIST 3 cm or more

Comparator: placebo

recurrence-free survival hazard ratio vs placebo (interim): 0.4 HR, median follow up 15 months

recurrence-free survival hazard ratio vs placebo (updated): 0.72 HR, median follow up 50 months

Adjuvant Study 1 (ACOSOG Z9001) · NCT00041197

Imatinib

Imatinib 400 mg for 36 months

400 mg · ITT

resected high-risk KIT positive GIST

Comparator: imatinib for 12 months

recurrence-free survival hazard ratio, 36 vs 12 months: 0.46 HR, median follow up 42 months

overall survival hazard ratio, 36 vs 12 months: 0.45 HR, median follow up 48 months

Adjuvant Study 2 (SSG XVIII) · NCT00116935

Regorafenib 1

Regorafenib

Regorafenib 160 mg, 3 weeks on 1 off

160 mg · ITT

GIST after imatinib and sunitinib

Comparator: placebo

progression-free survival hazard ratio vs placebo: 0.27 HR, primary analysis

GRID · NCT01271712

Ripretinib 2

Ripretinib

Ripretinib 150 mg

150 mg · ITT

GIST after imatinib, sunitinib and regorafenib

Comparator: placebo

progression-free survival hazard ratio vs placebo: 0.15 HR, primary analysis

INVICTUS · NCT03353753

Ripretinib

Ripretinib 150 mg

150 mg · ITT

GIST after imatinib (ITT n = 226)

Comparator: sunitinib 50 mg 4/2

progression-free survival hazard ratio vs sunitinib, ITT: 1.05 HR, primary analysis; not significant

INTRIGUE · NCT03673501

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.